Treatment of inflammatory diseases by carbon materials

Patent metadata

Field	Value
Publication number	US-2016193249-A1
Application number	US-201414915858-A
Country	US
Kind code	A1
Filing date	Sep 3, 2014
Priority date	Sep 3, 2013
Publication date	Jul 7, 2016
Grant date	—

Abstract

In some embodiments, the present disclosure pertains to methods of treating an inflammatory disease in a subject by administering a carbon material to the subject. In some embodiments, the carbon material selectively targets T cells in the subject. In some embodiments, the carbon material includes poly(ethylene glycol)-functionalized hydrophilic carbon clusters. In some embodiments, the administration of the carbon material to the subject reduces or inhibits T cell-mediated reactions in the subject. In some embodiments, the carbon material selectively targets T cells over other types of immune cells by preferential uptake into the T cells. In some embodiments, the carbon material reduces or inhibits proliferation of targeted T cells, reduces or inhibits cytokine production by targeted T cells, and reduces intracellular oxidant content in targeted T cells. In some embodiments, the present disclosure pertains to methods of modulating T cells ex-vivo by incubating the T cells with a carbon material.

First claim

What is claimed is:

1 . A method of treating an inflammatory disease in a subject, wherein the method comprises:
administering a carbon material to the subject,
where in the carbon material selectively targets T cells in the subject.

2 . The method of claim 1 , wherein the carbon material is selected from the group consisting of graphene quantum dots, graphene, graphene oxide, carbon black, activated carbon, carbon nanotubes, ultra-short single-walled carbon nanotubes, and combinations thereof.

3 . The method of claim 1 , wherein the carbon material has a serum half-life of between about 15 hours to about 40 hours.

4 . The method of claim 1 , wherein the carbon material has a length ranging from about 10 nm to about 100 nm.

5 . The method of claim 1 , wherein the carbon material has a length ranging from about 10 nm to about 50 nm.

6 . The method of claim 1 , wherein the carbon material is functionalized with a plurality of functional groups.

7 . The method of claim 6 , wherein the functional groups are selected from the group consisting of polyethylene glycols, polypropylene glycols, poly(acrylic acid), polysaccharides, poly(alcohols), poly(vinyl alcohol), polyamines, polyethylene imines, poly(vinyl amines), ketones, esters, amides, carboxyl groups, oxides, hydroxyl groups, alkoxy groups, and combinations thereof.

8 . The method of claim 6 , wherein the functional groups comprise polyethylene glycols.

9 . The method of claim 1 , wherein carbon material comprises one or more transport moieties.

10 . The method of claim 9 , wherein the transport moieties are selected from the group consisting of adamantane moieties (ADM), dimethyladamantane moieties, lipophilic moieties, small molecules, cannabinoids, epi-cannabinoids, peptides, saccharides, and combinations thereof.

11 . The method of claim 1 , wherein carbon material is oxidized.

12 . The method of claim 1 , wherein the carbon material comprises carbon nanotubes.

13 . The method of claim 12 , wherein the carbon nanotubes are selected from the group consisting of single-walled carbon nanotubes, ultra-short single-walled carbon nanotubes, multi-walled carbon nanotubes, double-walled carbon nanotubes, and combinations thereof.

14 . The method of claim 1 , wherein the carbon material comprises ultra-short single-wall carbon nanotubes.

15 . The method of claim 14 , wherein the ultra-short single-wall carbon nanotubes are functionalized with a plurality of functional groups.

16 . The method of claim 14 , wherein ultra-short single-wall carbon nanotubes comprise poly(ethylene glycol)-functionalized ultra-short single-walled carbon nanotubes.

17 . The method of claim 14 , wherein the ultra-short single-walled carbon nanotubes have lengths ranging from about 10 nm to about 100 nm.

18 . The method of claim 14 , wherein the ultra-short single-walled carbon nanotubes have lengths ranging from about 10 nm to about 50 nm.

19 . The method of claim 1 , wherein the administering occurs by a method selected from the group consisting of oral administration, inhalation, subcutaneous administration, topical administration, transdermal administration, intra-articular administration, intravenous administration, intraperitoneal administration, intramuscular administration, intrathecal injection, sub-lingual administration, intranasal administration, and combinations thereof.

20 . The method of claim 1 , wherein the subject is suffering from an inflammatory disease.

21 . The method of claim 20 , wherein the subject is a mammal.

22 . The method of claim 20 , wherein the subject is a human being.

23 . The method of claim 1 , wherein the inflammatory disease is selected from the group consisting of chronic inflammatory diseases, autoimmune diseases, T cell-mediated diseases, T cell-mediated autoimmune diseases, T cell-mediated inflammatory diseases, multiple sclerosis, rheumatoid arthritis, reactive arthritis, ankylosing spondylitis, systemic lupus erythematosus, glomerulonephritis, psoriasis, scleroderma, alopecia aerata, type 1 diabetes mellitus, celiac sprue disease, colitis, pernicious anemia, encephalomyelitis, vasculitis, thyroiditis, Addison's disease, Sjögren's syndrome, antiphospholipid syndrome, autoimmune cardiomyopathy, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative disorder, autoimmune peripheral neuropathy, pancreatitis, polyendocrine syndrome, thrombocytopenic purpura, uveitis, Behcet's disease, narcolepsy, myositis, polychondritis, asthma, chronic obstructive pulmonary disease, graft-versus-host disease, chronic graft rejection, and combinations thereof.

24 . The method of claim 1 , wherein the administering of the carbon material comprises daily administration.

25 . The method of claim 24 , wherein the daily administration lasts from about 3 days to about 3 months.

26 . The method of claim 24 , wherein the daily administration comprises from about 1 carbon material administration per day to about 5 carbon material administrations per day.

27 . The method of claim 1 , wherein the administering comprises carbon material administration at dosages that range from about 1 mg/kg of the subject's weight to about 5 mg/kg of the subject's weight.

28 . The method of claim 1 , wherein the administering of the carbon material reduces or inhibits T cell-mediated reactions in the subject.

29 . The method of claim 1 , wherein the carbon material selectively targets T cells over other types of immune cells.

30 . The method of claim 1 , wherein the carbon material selectively targets T cells by preferential uptake into the T cells.

31 . The method of claim 1 , wherein the carbon material reduces or inhibits proliferation of targeted T cells.

32 . The method of claim 1 , wherein the carbon material reduces or inhibits cytokine production by targeted T cells.

33 . The method of claim 1 , wherein the carbon material reduces or inhibits T-cell signaling by targeted T cells.

34 . The method of claim 1 , wherein the carbon material reduces intracellular oxidant content in targeted T cells.

35 . The method of claim 1 , wherein carbon material does not induce apoptosis in targeted T cells.

36 . A method of modulating T cells, wherein the method comprises incubating the T cells with a carbon material.

37 . The method of claim 36 , wherein the carbon material is selected from the group consisting of graphene quantum dots, graphene, graphene oxide, carbon black, activated carbon, carbon nanotubes, ultra-short single-walled carbon nanotubes, and combinations thereof.

38 . The method of claim 36 , wherein the carbon material is functionalized with a plurality of functional groups.

39 . The method of claim 38 , wherein the functional groups are selected from the group consisting of polyethylene glycols, polypropylene glycols, poly(acrylic acid), polysaccharides, poly(alcohols), poly(vinyl alcohol), polyamines, polyethylene imines, poly(vinyl amines), ketones, esters, amides, carboxyl groups, oxides, hydroxyl groups, alkoxy groups, and combinations thereof.

40 . The method of

Assignees

• Univ Rice William M
• Baylor College Medicine

Inventors

• Tour James M
• Beeton Christine
• Huq Redwan U
• Inoue Taeko
• Pautler Robia G
• Samuel Errol L G

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title